l e t t e r s Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer 1 . Cell entry of HCV 2 and other pathogens 3-5 is mediated by tight junction (TJ) proteins, but successful therapeutic targeting of TJ proteins has not been reported yet. Using a human liver-chimeric mouse model 6 , we show that a monoclonal antibody specific for the TJ protein claudin-1 (ref. 7) eliminates chronic HCV infection without detectable toxicity. This antibody inhibits HCV entry, cell-cell transmission and virus-induced signaling events. Antibody treatment reduces the number of HCV-infected hepatocytes in vivo, highlighting the need for de novo infection by means of host entry factors to maintain chronic infection. In summary, we demonstrate that an antibody targeting a virus receptor can cure chronic viral infection and uncover TJ proteins as targets for antiviral therapy.
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Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer 1 . Cell entry of HCV 2 and other pathogens [3] [4] [5] is mediated by tight junction (TJ) proteins, but successful therapeutic targeting of TJ proteins has not been reported yet. Using a human liver-chimeric mouse model 6 , we show that a monoclonal antibody specific for the TJ protein claudin-1 (ref. 7) eliminates chronic HCV infection without detectable toxicity. This antibody inhibits HCV entry, cell-cell transmission and virus-induced signaling events. Antibody treatment reduces the number of HCV-infected hepatocytes in vivo, highlighting the need for de novo infection by means of host entry factors to maintain chronic infection. In summary, we demonstrate that an antibody targeting a virus receptor can cure chronic viral infection and uncover TJ proteins as targets for antiviral therapy.
The TJ protein claudin-1 (CLDN1) mediates hepatitis C virus (HCV) entry into host cells 2 . TJs are also implicated in the entry of other pathogens including dengue virus 5 , adenovirus 3 , coxsackievirus 3 and shigella 4 . However, the role of TJ proteins in viral pathogenesis and as antiviral targets is unknown. To investigate this we used a recently developed inhibitory CLDN1-specific monoclonal antibody (mAb) 7 and the human chimeric uPA-SCID (urokinase-type plasminogen activator-transgenic severe combined immunodeficiency) mouse model 6 . Owing to discontinuation of research in chimpanzees for ethical reasons, this mouse model is the only available model that supports robust long-term chronic HCV infection. Although these mice lack a functional immune system, precluding the study of immune-mediated events, they have substantially contributed to our understanding of viral pathogenesis and the development of antivirals [8] [9] [10] [11] .
First, we analyzed CLDN1 expression in the chimeric liver using a commercially available mAb that recognizes human and mouse CLDN1 (Supplementary Fig. 1 ). Confocal imaging demonstrated that the majority of CLDN1 on human hepatocytes co-localized with apical marker CD10, demonstrating the formation of bile canalicular structures (Fig. 1a) . A minor pool of protein was detected at the basolateral membrane as identified with cytokeratin-8 staining 12 ( Fig. 1a and data not shown). Comparative staining of normal human liver tissue demonstrated comparable subcellular localization (Fig. 1a) . Transmission electron microscopic (TEM) analysis confirmed that hepatocytes in the chimeric mouse liver form TJs that were structurally indistinguishable from those in human liver tissue ( Supplementary Fig. 2a,b) . The similar localization of hepatocellular CLDN1 and hepatocyte architecture suggests that the uPA-SCID chimeric mouse is a relevant model to evaluate CLDN1 as a therapeutic target.
Next, we characterized the subcellular localization of CLDN1 recognized by the inhibitory CLDN1-specific mAb (OM-7D3-B3) when administered intraperitoneally in vivo. TEM and immunogold labeling of the CLDN1 mAb showed reactivity with basolateral and Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody l e t t e r s sinusoidal hepatocyte membranes in vivo (Fig. 1b) , whereas we failed to detect staining of TJs (Fig. 1b) . Basolateral membrane staining was confirmed using live-cell imaging of polarized hepatoma HepG2 cells (Fig. 1c) 13 . Collectively, these data suggest that the CLDN1-specific mAb predominantly binds to nonjunctional pools of CLDN1 on the hepatocyte basolateral membrane in vivo.
To investigate the antiviral effect of this CLDN1-specific mAb, we administered to chimeric uPA-SCID mice CLDN1-specific (n = 5) or control isotype-matched irrelevant mAb (n = 4) 1 day before inoculation, and 1 and 5 days after infection with a primary HCV genotype 1b serum. The CLDN1-specific mAb provided complete and sustained protection from infection as evidenced by undetectable HCV RNA in the sera for up to 6 weeks after infection ( Fig. 2a and Supplementary  Table 1 ). In contrast, all control-mAb-treated mice became infected (Fig. 2a) . Similar results were observed following infection with an HCV of the difficult-to-treat genotype 4 (isolate ED43 (ref. 14)), Fig. 2b and Supplementary Table 1) , demonstrating a significant level of anti-viral activity (P < 0.0002, pooled data from experiments of both genotypes, Mann-Whitney test). Pharmacokinetic studies showed that CLDN1-specific mAb levels declined rapidly and were undetectable 2 weeks after administration (Fig. 2f,g ). Collectively, these data show that short-term administration of a CLDN1-specific mAb prevents de novo HCV infection and suggests that it might be used to prevent HCV re-infection during liver transplantation.
To investigate the effect of the CLDN1-specific mAb on chronic HCV infection, we used mice persistently infected with the cell culture-derived HCV (HCVcc) strain Jc1 (genotype 2a/2a chimera) 15 , a JFH1-derived 16 prototype strain. Persistently infected mice (24-50 days after infection) were given four doses total (one in each week of the study period) of CLDN1-specific (n = 5) or control mAbs (n = 4). All CLDN1-specific mAb-treated mice had undetectable HCV RNA levels in the blood after 2 to 4 injections ( Fig. 2c and Supplementary  Table 1 ) and, except for one case, animals remained free of virus until the end of the study period. The relapsed mouse showed a low antibody serum concentration during the early treatment phase (Fig. 2h) . However, low levels of mAbs did not always correlate with relapse ( Fig. 2i,j) . Sequencing and functional analysis of viral envelope glycoproteins from antibody-treated mice in HCV pseudoparticles (HCVpp) and HCVcc ( Supplementary Fig. 3a-e) suggested that the relapse was unlikely to be explained by the presence of resistant variants that escaped the CLDN1-specific mAb ( Supplementary  Fig. 3c,d ) or to CLDN1-independent cell entry ( Supplementary  Fig. 3e) . Notably, human hepatocytes engrafted into uPA-SCID mice expressed lower CLDN6 levels than Huh7.5.1 cells ( Supplementary  Fig. 4a-d) . The mAb concentration peaked during the treatment period and declined rapidly following discontinuation of mAb injection (Fig. 2h) . Similar results were observed in four additional HCV Jc1-infected and CLDN1-specific mAb-treated mice with follow-up of 3 weeks (data not shown).
CLDN1 mAb also induced viral clearance from mice chronically infected with HCVcc VL-JFH1 (genotype 1b/2a chimera) (n = 5), a well-characterized strain 17 encoding the structural proteins from a highly infectious HCV neutralization escape variant isolated from a patient undergoing liver transplantation ( Fig. 2d and (Fig. 2i) . The therapeutic effect was robust (HCV RNA decline > 2 logs), sustained (until the end of the study period corresponding to 11 weeks) and significant (P < 0.0007, pooled data for experiments of both genotypes, MannWhitney test). Furthermore, a similar effect was observed in mice chronically infected with HCV genotype 2a serum (Fig. 2e and Supplementary Table 1) . Mice infected with primary isolates of HCV genotype 4 (n = 4) also showed a marked and time-dependent decrease in HCV RNA levels ( Supplementary Fig. 5a ) with no viral rebound and stable function of the engrafted human hepatocytes as shown by serum albumin levels (Supplementary Fig. 5b ). In summary, these data show that a CLDN1-specific mAb can clear chronic HCV infection in vivo and exhibits antiviral activity against different viral genotypes. These findings suggest CLDN1 as a therapeutic target in a clinically relevant animal model.
To assess antibody safety, we analyzed the histopathology of chimeric uPA-SCID mouse livers. Human hepatocyte-specific staining npg l e t t e r s demonstrated similar repopulation and structure of human hepatocytes in HCV Jc1-infected mice treated with the control or CLDN1-specific mAb (Supplementary Fig. 6a ). TEM analysis of chimeric-infected livers of treated mice showed no detectable alteration in hepatocyte morphology or TJ ultrastructure (data not shown). Human albumin, transaminases (ALT, AST) and total bilirubin levels remained stable following antibody administration and were similar in control and CLDN1-specific mAb-treated mice at all time points tested ( Supplementary Fig. 6b-e) .
To assess the functional integrity of CLDN1-mAb-treated human hepatocytes in mice, we challenged the mice with HCV of a different strain and genotype. CLDN1-specific mAb-treated animals previously protected from HCV infection (Fig. 2a) supported viral infection following mAb elimination (Supplementary Fig. 6f ). These functional data corroborate the presence of fully viable and functional hepatocytes following anti-CLDN1 mAb treatment and exclude adverse effects on hepatocyte function in vivo.
To address potential side effects of the CLDN1-specific mAb in other organs and tissues, we assessed antibody binding to human and murine CLDN1 (Supplementary Fig. 7a-g ). The antibody-bound primary mouse hepatocytes and 293T cells expressing murine CLDN1 with an apparent K d of 83.6 ± 14.1 nM compared to the apparent K d for human CLDN1 expressed in 293T cells (17.05 ± 1.14 nM) (Supplementary Fig. 7g) . Moreover, the latter was in a similar range as the apparent K d of CLDN1-specific mAb binding to human hepatocytes 7 . Next we measured in vivo biodistribution in BALB/c mice and observed enrichment in skin, kidneys, lungs, intestines and liver ( Supplementary Fig. 8a,b) . Toxicity studies in BALB/c mice including clinical (data not shown), biochemical and hematological parameters as well as histopathological analyses did not reveal any toxicity ( Supplementary Fig. 9 and Supplementary Tables 2 and 3) . Because TJs play a key role in intestinal paracellular permeability, we investigated the effect of the CLDN1-specific mAb on intestinal barrier function in vivo. The CLDN1-specific mAb had no effect on intestinal paracellular permeability ( Supplementary Fig. 8c ) or total intestinal transit time ( Supplementary Fig. 8d ), in contrast to irradiation, which was used as a positive control for intestinal injury. Additional ex vivo studies showed that the CLDN1-specific antibody had no detectable effects on paracellular permeability ( Supplementary Fig. 8e ) or tissue conductance in the small intestine or colon ( Supplementary  Fig. 8f ). Moreover, the mAb had no effect on the transepithelial electrical resistance of intestinal Caco-2 cells ( Supplementary  Fig. 8g ), which express abundant CLDN1 levels ( Supplementary  Fig. 8h ), or on TJ function in hepatoma HepG2 cells 18 . Whereas CLDN1 knockdown significantly reduced TJ integrity (P < 0.001, t-test) in polarized HepG2 cells ( Supplementary Fig. 10a,b) , the CLDN1-specific mAb had no impact (Supplementary Fig. 10c ). Furthermore, flow cytometry experiments measuring CLDN1 cell surface expression suggested that the CLDN1-specific mAb did not promote cellular CLDN1 internalization (Supplementary Fig. 10d ). Finally, a detailed analysis of cytokine mRNA expression in antibodytreated mice did not reveal evidence for antibody-induced inflammatory changes in the mouse jejunum (data not shown). Collectively, these data exclude major toxicity or side effects induced by the CLDN1-specific mAb in mice. Because the rat antibody did not interact with the mouse Fc receptor, immune-mediated adverse effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC), cannot be assessed in this model. Humanization of the antibody using an IgG4 backbone-a well-established strategy to minimize ADCC 19 -is underway for its clinical development.
To explore the antiviral mechanism of the CLDN1-specific mAb, we performed both in vitro and in vivo studies. Using protein association studies and a Förster resonance energy transfer (FRET)-based assay, we found that the CLDN1-specific mAb interfered with CD81-CLDN1 co-receptor complex formation ( Supplementary  Fig. 11a )-a key step required for HCV entry 20 . Co-receptor l e t t e r s perturbation most likely occurs at the hepatocyte basolateral membrane as shown by immunofluorescence studies of polarized HepG2 cells or immunogold affinity labeling of hepatocytes (Fig. 1b,c) . Furthermore, we demonstrate that the CLDN1-specific mAb significantly inhibits cell-free and cell-cell routes (P < 0.01, t-test) of transmission ( Supplementary Fig. 11b-e) . Of note, inhibition of cellcell transmission led to a marked decrease of virus spread in hepatoma cells when the CLDN1-specific mAb was added 48 h after infection (Supplementary Fig. 11e ). The ability of the antibody to inhibit cellfree and cell-cell infection may explain, at least partially, the antiviral effects of the CLDN1-specific mAb to cure persistent HCV infection in vivo. As this mAb impaired neither HCV replication nor assembly and release ( Supplementary Fig. 11f,g ), we conclude that the mAb acts predominantly by interfering with HCV entry. Because claudins can modulate signaling pathways 21 , we investigated whether the antibody modulated the microRNA (miRNA) and kinome profiles of persistent HCV-infected Huh7.5.1 cells. Consistent with previous observations, our deep sequencing studies confirmed that HCV infection modulates miRNA profiles in Huh7.5.1 cells. However, the CLDN1-specific mAb had no detectable effect on miRNA expression (Supplementary Fig. 12) .
HCV binding to hepatocellular CD81 and associated receptors activates EGFR and mitogen-activated protein kinase (MAPK) signaling 22, 23 . HCV Jc1 infection increased ERK1/2 phosphorylation, and this was reversed by the CLDN1-specific mAb (Fig. 3a,b) . The significance of HCV-induced MAPK signaling was supported by analyzing liver biopsies from HCV-infected patients. Liver biopsies from HCV-infected patients showed a significant (P < 0.01, Mann-Whitney test) 2.45-fold increase in p-ERK1/2 levels over that observed in the control (Fig. 3c,d, Supplementary Fig. 13a and Supplementary Table 4 ). We observed an antiviral effect of small-molecule inhibitors targeting MAPK signaling (Fig. 3e) at nontoxic concentrations 9, 24 (Supplementary Table 5 ). To confirm the effect of the CLDN1-specific mAb on HCV-induced signaling in liver tissue from HCV-infected patients (Supplementary Table 4) , freshly isolated liver biopsies were treated ex vivo with CLDN1-specific or control mAb, and we observed a reduction of ERK1/2 phosphorylation compared to control-treated biopsies ( Fig. 3f and Supplementary Fig. 13b ). Fresh liver biopsies were divided in two equal pieces and maintained in DMEM medium supplemented with 10% fetal calf serum and 100 µg/ml control mAb or CLDN1-specific mAb for 4 h, respectively. Expression of p-ERK1/2, total ERK1/2 and ACTIN was determined by western blot analysis. (Representative full-length blots are presented in Supplementary Fig. 13b .) (g) p-EGFR, p-ERK1/2 and total ERK1/2 of serum starved Huh7.5.1 cells treated with antibodies and EGF was quantified by western blot analysis. (Full-length blots are presented in Supplementary Fig. 13c ). (h) EGF-induced ERK phosphorylation in the presence of CLDN1-specific or control mAb. p-ERK1/2 and total ERK1/2 western blot signals described in g were quantified using a Typhoon Trio laser scanner and ImageQuant Software. Values are expressed as relative ratio of p-ERK1/2 to total ERK1/2 densities (two independent experiments ± s.e.m.). (i) Model of HCV-induced signal transduction during cell entry (left panel) and its impairment by CLDN1-specific mAb (right panel). Left panel: (1) HCV entry is dependent on EGFR signaling, which promotes CD81-CLDN1 co-receptor interactions 9, 24 ; at the same time, viral binding to the target cell induces (2) EGFR phosphorylation and signaling through CD81-EGFR interactions 23 and (3) MAPK signaling by cross-talk 22 . Right panel: proposed model that the CLDN1-specific mAb impairs virus-induced MAPK/ERK1/2 signaling by interfering with CD81/CLDN1-MAPK cross-talk without impairing direct EGF-induced ERK1/2 phosphorylation. *P < 0.05, **P < 0.01, ***P < 0.0001 (Student's t-test (b,e), Mann-Whitney test (d)).
npg l e t t e r s
These studies show that HCV infection activated MAPK signaling and CLDN1-specific mAb partially reversed this virus-dependent signaling event and did so without inhibiting ERK activation by the physiological EGFR ligand EGF (Fig. 3g,h and Supplementary  Fig. 13c ). These data suggest a model in which the anti-CLDN1 mAb impairs HCV-induced cross-activation of EGFR and ERK by interfering with CD81-CLDN1 association (Fig. 3i) . Because MAPK signaling has been shown to be relevant for the HCV life cycle, including viral entry 24, 25 , it is likely that this interference contributes to the ability of the antibody to clear an established infection. Finally, we performed mechanistic studies in chimeric mice to study the consequences of the observed mechanistic findings for viral clearance in vivo. Using fluorescence in situ hybridization (FISH) with HCV-and human GAPDH-RNA-specific probes (Fig. 4a) , we demonstrate that the CLDN1-specific mAb results in a dose-and time-dependent decrease in the number of HCV-infected cells leading to their final elimination (Fig. 4b) . The decline of HCV-infected hepatocytes paralleled the decline in peripheral HCV RNA levels, showing a monophasic decline (Fig. 4b and Supplementary Fig. 14) . Notably, the baseline frequency of HCV-infected hepatocytes (Fig. 4b) in the chimeric mouse liver were comparable to those reported in chronically infected human liver 26 .
Assuming an inhibition of entry ( Supplementary Fig. 11 ) and a negligible effect on viral replication or assembly ( Supplementary  Fig. 11f,g ), mathematic modeling predicts a time-dependent elimination of virus-infected hepatocytes with concomitant lack of de novo infection. Applying this model, we estimated the half-life of infected cells to be ~1.3 days for HCV genotype 2a and 5.4 days for HCV genotype 4, which is in the range of hepatocyte half-lives reported in patients 27 . Indeed, HCV has been reported to promote apoptosis 28 ( Supplementary Fig. 15 ). During serum HCV RNA decline, virusinfected hepatocytes are constantly replaced by noninfected hepatocytes resulting in viral control and clearance. This model is supported by both FISH analyses of liver tissue sections (Fig. 4) and cell culture studies where the CLDN1-specific mAb eliminates HCV-infected cells (Supplementary Fig. 15c,d) . The different half-lives of HCV-infected cells and the magnitude of virus-induced cell death may explain the varying magnitude of the decline in viral load for diverse HCV strains (Supplementary Figs. 5a and 14) 27 .
Collectively, we demonstrate that a host-targeting entry inhibitor clears chronic viral infection (Fig. 2c-e) . Our results show that viral entry and spread are required for persistent infection in vivo and that CLDN1 is a valid target to prevent and treat chronic HCV infection. The interaction of the mAb with nonjunctional pools of CLDN1 (Fig. 1b,c) that complex with the viral co-receptor CD81 (Supplementary Fig. 11a ) may explain the non detectable toxicity (Supplementary Figs. 6a-f, 8c-g and 9 and Supplementary  Tables 2 and 3) .
In summary, therapeutic administration of a CLDN1-specific mAb demonstrates activity against several HCV genotypes ( Fig. 2 and Supplementary Figs. 5 and 11b ) without detectable toxicity (Supplementary Figs. 6,8,9 and Supplementary Tables 2 and 3) . The absence of detectable viral resistance (Supplementary Fig. 3 ) suggests that CLDN1 is an antiviral target with a high genetic barrier for resistance. Although strain-dependent use of CLDN1 and CLDN6 has been described in hepatoma cells 29 , our data suggest that CLDN1 is essential for HCV infection in vivo and low expression levels of CLDN6 and CLDN9 in human hepatocytes 29, 30 ( Supplementary  Fig. 4 ) appear to preclude a relevant entry function of these molecules in vivo in the human chimeric mouse model.
In contrast to clinically licensed direct-acting antivirals, such as HCV protease, NS5A or polymerase inhibitors the CLDN1-specific mAb eliminates viral infection in monotherapy in the state-of-the-art animal model (Fig. 2 and Supplementary Fig. 5a ) without detectable resistance (Supplementary Fig. 3 ). These features are likely due to its unique mechanism of action targeting a host factor ( Supplementary  Fig. 11a ) that is essential for viral persistence in vivo as well as for modulating signaling of virus-infected cells (Fig. 3) , likely contributing to clearance. Our data suggest that antibodies or small molecules targeting CLDN1 are promising candidates to prevent liver graft infection and to eliminate chronic HCV infection. Finally, similar antimicrobial strategies may be designed for a broad range of pathogens that utilize TJ proteins as host factors including dengue virus, coxsackievirus, adenovirus and shigella [3] [4] [5] .
MeTHodS
Methods and any associated references are available in the online version of the paper. Antibodies. The human CLDN1-specific (OM-7D3-B3, IgG2b, rat 7 ), CLDN6-specific (WU-9E1-G2, IgG2b, rat 30 ), CLDN9-specific (YD-4E9-A2, IgG2b, rat 30 ) mAbs have been described previously and were produced by Aldevron Freiburg. HCV E2-specific AP33 (mouse) 17 , E1-specific IGH433 (human) 7 , E2-specific CHB-23 (human) 17 mAbs and patient-derived HCV-specific IgG 7 have been described. Control mAb (rat IgG2b clone LTF-2, Bio X Cell), human CLDN1-specific (Life Technologies, rabbit; R&D, rat polyclonal), human CD10-specific (clone 56C6, Vector Laboratories, mouse), human CD81-specific (clone 2s131, mouse), human CK18-specific (clone VP-C414, Vector Laboratories, mouse), Alexa-fluor 488-conjugated IgG rabbit-specific, Alexa-fluor 488-conjugated IgG mouse-specific, Alexa-fluor 488-conjugated IgG rat-specific and Alexa-fluor 594-conjugated IgG mouse-specific Abs (Invitrogen, goat) were used for fluorescent imaging as described 31 . ERK1/2 (rabbit, Cell Signaling), pERK1/2 (Thr202, Tyr204, mouse, clone E10, Cell Signaling) and beta-actin (clone AC-15, mouse, Sigma)-specific antibodies and alkaline-phosphatase (AP)-labeled (goat, GE Healthcare) as well as IRDye 800CW-conjugated goat anti-rabbit and IRDye 680-conjugated goat anti-mouse (Li-Cor Biosciences) secondary antibodies were used for immunoblot analyses. Rabbit anti-rat bridging antibody (Cappel #55704) was used for immunogold labeling.
Cell lines. Huh7.5.1, Huh7.5-GFP, Huh7.5 shCD81.1, 293T, HepG2 DsRed-CD81 and Caco-2 cells were cultured as described 9, [32] [33] [34] [35] .
Imaging of CLDN1 in human and chimeric livers. Chimeric mouse and human liver samples were formalin fixed and paraffin embedded. Human liver tissue was obtained from patients with HCV undergoing liver transplantations or from normal livers taken from surplus donor tissue used for reduced size transplantation. Informed consent from each patient was obtained with regional ethics committee approval (project number 04/Q2708/40). Sections were subjected to low-temperature antigen-retrieval pretreatment, followed by fluorescent detection of CLDN1, CD10 or CK18, as previously described 31 . Labeled sections were visualized using laser scanning confocal microscopy (Zeiss LSM 780, 100 x Plan Apochromat 1.4NA oil immersion objective). Background and autofluorescence of tissue samples were corrected throughout and 3D composite images were generated using the Zeiss Zen analysis software.
TEM and immunogold labeling of CLDN1 in vivo.
Human liver-chimeric mice were injected with 500 µg control or CLDN1-specific mAb and euthanized 5 h later. Mice were perfused with PBS for 3 min through portal vein infusion followed by 5 min perfusion with 4% electron microscopy (EM)-grade paraformaldehyde (PFA). Livers were harvested, minced in 3-mm pieces and fixed in 4% PFA at room temperature for 24 h. Subsequently liver pieces were placed in PBS and kept at 4 °C before processing for EM. Prior to freezing in liquid nitrogen the tissue were infiltrated with 2.3 M sucrose in PBS containing 0.2 M glycine for 15 min. Frozen samples were sectioned at −120 °C, the sections were transferred to formvar-carbon-coated copper grids. Grids were floated on PBS at room temperature (RT) until the immunogold labeling was carried out at RT on a piece of parafilm using control or CLDN1-specific mAb, rabbit anti-rat bridging antibody and 10 nm (for CLDN1-specific mAb) or 15 nm (for isotype control mAb) protein-A gold. Contrasting and embedding of the labeled grids was carried out on ice in 0.3% uranyl acetate in 2% methyl cellulose for 10 min. Grids were examined in a JEOL 1200EX TEM and images were recorded with an AMT 2k CCD camera. Human liver-chimeric mice. Human liver-chimeric mice were produced by transplanting cryopreserved human hepatocytes into the spleen of 3-week-old homozygous urokinase-type plasminogen activator-transgenic severe combined immunodeficiency-beige (uPA-SCID-bg) mice 6,36 of both sexes. Human hepatocytes were purchased from Becton Dickinson or isolated as described 7, 9 .
In vivo experimentation. For prevention studies, chimeric uPA-SCID mice were intraperitoneally injected with 500 µg CLDN1-specific or control mAb at day −1 before and days 1 and 5 after inoculation of a genotype 1b or 4 HCV-infected serum. HCV infection was performed as previously described 6 Table 4 ). Liver biopsy tissues from patients were analyzed as described 37 . In brief, liver tissue was lysed in 100 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA, 0.1% Triton X-100, 10 mM NaF, 1 mM PMSF, and 1 mM sodium ortho-vanadate during mechanical homogenization followed by 20 min incubation on ice. Lysates were cleared by centrifugation at 4 °C and 21,000g for 5 min before immunoblot analysis of 5 µg protein per sample.
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For ex vivo stimulation, fresh liver biopsies were divided in two equal pieces and incubated for 4 h at 37 °C in DMEM medium supplemented with 10% FCS and 100 µg/ml control or CLDN1-specific mAb, respectively.
Analysis of protein expression and phosphorylation. Immunoblots of cell lysates using ERK1/2-specific antibodies were performed using Hybond-P membranes and visualized using ECF substrate (GE Healthcare), according to the manufacturer's protocol. Fluorescence emission was detected using Typhoon Trio high-performance fluorescence scanner (GE Healthcare) and quantified using Image Quant TL software (GE Healthcare). Phospho-array analysis was performed using Proteome Profiler Human Phospho-kinase Array (R&D Systems) as described by the manufacturer. For imaging, blots were incubated with ECL (GE Healthcare) and exposed to ECL Hyperfilm (GE Healthcare). Phospho-kinase array results were quantified by integrating the dot blot densities using ImageJ software (NIH). Immunoblots from biopsies were analyzed as described 24 .
Inhibition of HCV infection by protein kinase inhibitors. Huh7.5.1. cells were plated in 96-well plates (2 × 10 3 cells/well) and infected 24 h later for 3 days with HCVcc Luc-Jc1. Medium was then removed and replaced with medium containing 10 µM erlotinib (LC Laboratories) or UO126 (Calbiochem) and final concentration of 1% DMSO. Control medium contains only 1% DMSO. Three days later, HCV replication was quantified by luciferase activity measurement.
EGF-induced MAPK activation. Huh7.5.1 cells were serum starved for 4 h before 1 h incubation with 100 µg/ml control or CLDN1-specific mAb and 15-min incubation with increasing concentrations (1, 10 and 100 ng/ml) of EGF. p-EGFR, p-ERK1/2 and total ERK were detected by western blot analysis. Quantification was performed using a Typhoon Trio laser scanner and ImageQuant Software (GE Healthcare).
FISH analyzes of human chimeric livers. Liver samples from mice were collected during necropsy, immediately embedded in optimal cutting temperature compound (OCT) and frozen in liquid nitrogen chilled 2-methylbutane. Tissues were then stored at −80 °C until use. Sections (10 µm) were cut at cryostat (Leica), fixed overnight in 4% formaldehyde at 4 °C and hybridized, as previously described 26 , with the following modifications. Briefly, tissue sections were pretreated by boiling (90-95 °C) in pretreatment solution (Affymetrix -Panomics) for 1 min, followed by a protease QF (Affymetrix -Panomics) digestion for 10 min at 40 °C. Hybridization was performed using probe sets against JFH-1 HCV RNA (target region 4513-6253) and against human GAPDH mRNA (VA6-12786-06, Affymetrix-Panomics). Preamplification, amplification and detection were performed according to provider's protocol. Images were acquired with a LSCM (LSM710, Carl Zeiss Microscopy) and Zen2 software, using the same settings for all the tissues analyzed. Five to seven random fields were selected from each section, based only on the presence of human GAPDH signal to ensure the presence of human hepatocytes. Images were then acquired also including the channel for the HCV detection. Image analysis was performed using ImageJ and CellProfiler software, with a customized pipeline. 
